Category: biotech

.After a few years in biotech, Mike Quigley, Ph.D., is coming back to the pharma crease, taking up the best scientific research location at Sanofi.Quigley

.Sanofi has brought in an overdue entry to the radioligand party, paying out 100 million euros ($ 110 million) in advance for worldwide rights to

.Sanofi has actually ceased a stage 2 trial of Denali Therapeutics-partnered oditrasertib in multiple sclerosis. The French drugmaker tore the RIPK1 prevention ordeal from its

.Sangamo Rehabs has identified a shortcut to market for its Fabry illness applicant, lining up with the FDA on a pathway that could slash three

.Sage Rehabs’ newest try to reduce its pipe and labor force will certainly view a 3rd of the biotech’s staff members heading for the leaves

.Matt Gline is back with a new ‘vant’ company, after the Roivant Sciences chief executive officer paid for Bayer $14 million in advance for the

.After forming a gene treatment alliance with Dyno Rehabs in 2020, Roche is actually back for additional.In a brand new package potentially worth greater than

.Roche has actually come back the liberties to UCB’s anti-tau antibody bepranemab, bowing out a $120 thousand bank on the Alzheimer’s illness drug candidate on

.Roche is actually keeping out chances that its own injectable being overweight prospect could eventually display 25% weight loss in late-stage trials, the pharma’s mind

.Roche’s chronic coughing system has faltered to a halt. The drugmaker, which axed the plan after the medicine candidate dissatisfied in period 2, revealed (PDF)